Evening primrose oil and gynaecomastia is a topic that attracts considerable interest, particularly among men seeking alternatives to conventional treatment for enlarged male breast tissue. Gynaecomastia — the benign growth of glandular breast tissue in males — can cause significant distress, prompting some to explore herbal supplements such as evening primrose oil (EPO). However, the evidence supporting EPO for this condition is extremely limited, and no UK clinical guidelines from NICE, the NHS, or the MHRA recommend its use. This article examines what EPO contains, what the evidence shows, potential risks, and when to seek medical advice.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an oestrogen–androgen imbalance; causes include physiological changes, medications, systemic conditions, and herbal supplements with hormonal activity.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery swelling beneath one or both nipples. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular growth. Gynaecomastia is relatively common, affecting an estimated 30–60% of adolescent boys during puberty, as well as older men, particularly those aged 50 and above (NICE CKS: Breast symptoms – male; NHS: Gynaecomastia).

The underlying cause is typically an imbalance between oestrogen and androgen activity in breast tissue. Oestrogens stimulate ductal proliferation, whilst androgens — primarily testosterone — counteract this effect. When this balance is disrupted, glandular growth can occur. Common causes include:

• Physiological changes during puberty or ageing

• Medications such as spironolactone, cimetidine, anabolic steroids, anti-androgens (e.g., bicalutamide), finasteride, ketoconazole, digoxin, and some antipsychotics

• Medical conditions including hypogonadism, hyperthyroidism, liver cirrhosis, and chronic kidney disease

• Recreational substances such as alcohol; cannabis has been listed as a possible cause in some sources, though the evidence for this association is mixed and not conclusive

• Herbal or dietary supplements with oestrogenic or anti-androgenic properties

In many cases, no identifiable cause is found, and the condition is classified as idiopathic. Whilst gynaecomastia is not typically dangerous, it can cause significant psychological distress and physical discomfort. A thorough clinical assessment is essential to rule out underlying pathology, including the rare but important possibility of male breast cancer, which tends to present as a harder, irregular, or unilateral mass.

NICE guidance (NG12: Suspected cancer — recognition and referral) recommends that GPs consider an urgent two-week-wait referral for males with unexplained breast symptoms that could indicate cancer, including a unilateral, hard, or irregular breast lump; skin changes such as dimpling or puckering; or unilateral nipple changes (including discharge or retraction), particularly in those aged 50 and over. Any unexplained breast changes in males should be assessed promptly.

Evening Primrose Oil: What It Contains and How It Works

Evening primrose oil is a food supplement containing GLA and linoleic acid; it is not MHRA-licensed for gynaecomastia and has no proven direct oestrogenic or anti-gynaecomastia activity.

Evening primrose oil (EPO) is a plant-derived supplement extracted from the seeds of Oenothera biennis. It is widely available over the counter in the UK. Its primary active constituents are:

• Gamma-linolenic acid (GLA) — an omega-6 fatty acid comprising approximately 8–10% of the oil

• Linoleic acid — the predominant fatty acid, making up around 70% of the oil's composition

GLA is thought to exert anti-inflammatory effects by modulating prostaglandin synthesis, including promoting the production of prostaglandin E1 (PGE1). This mechanism has been proposed as the basis for its use in inflammatory and hormonal conditions. EPO is sometimes used for conditions such as premenstrual syndrome and menopausal symptoms, though it is important to note that high-quality clinical evidence of meaningful benefit for these indications is limited and inconsistent.

Of particular relevance to gynaecomastia, some researchers have proposed — based largely on older, small-scale studies in female mastalgia — that GLA may theoretically reduce the sensitivity of breast tissue to prolactin, a hormone that can contribute to breast tissue growth. However, these mechanisms are hypothetical and have not been clinically proven in male gynaecomastia. Extrapolating findings from female mastalgia studies to male breast tissue is speculative and not supported by robust evidence.

EPO does not appear to have direct oestrogenic activity, which distinguishes it from phytoestrogen-containing supplements such as red clover or soya isoflavones. It is classified as a food supplement in the UK and is not licensed as a medicinal product by the MHRA for the treatment of gynaecomastia or any other condition. Its use in this context is therefore outside any formally approved indication.

Evidence and Clinical Guidance on Herbal Supplements for Gynaecomastia

No NICE, NHS, or MHRA guidance recommends evening primrose oil for gynaecomastia, and no robust clinical trials support its use; evidence is limited to anecdotal reports and female mastalgia studies.

The evidence base for using evening primrose oil specifically in the management of gynaecomastia is extremely limited. There is no official clinical guidance from NICE, the NHS, or the MHRA recommending EPO as a treatment for this condition.

Interest in EPO for gynaecomastia largely stems from anecdotal reports and older studies examining its role in benign breast conditions in women — particularly cyclical mastalgia — rather than male breast tissue enlargement. Importantly, Cochrane reviews and other systematic assessments of EPO for mastalgia have not demonstrated clear superiority over placebo. Extrapolating these findings to male gynaecomastia is therefore unsupported. Robust, peer-reviewed clinical trials specifically investigating EPO in male gynaecomastia are absent from the current literature, and no reliable claims about its efficacy or safety for this purpose can be made.

For clinically significant gynaecomastia, management aligned with NICE CKS guidance typically follows a stepwise approach:

• Watchful waiting for physiological gynaecomastia in adolescents, as it often resolves spontaneously within 6–24 months

• Addressing underlying causes, including reviewing and adjusting causative medications where possible

• Pharmacological options such as tamoxifen or raloxifene, used off-label and typically initiated only under specialist supervision, in cases of painful or persistent gynaecomastia; aromatase inhibitors are generally not recommended for this indication in UK practice (BNF; NICE CKS)

• Surgical intervention (subcutaneous mastectomy) for longstanding or severe cases

Patients should be cautious about self-treating with supplements in place of seeking a formal medical assessment, particularly where an underlying hormonal or systemic condition may be present.

Risks, Side Effects, and Drug Interactions to Be Aware Of

EPO is generally well tolerated but may cause gastrointestinal upset, headache, and theoretically increased bleeding risk with anticoagulants; it should be avoided in epilepsy and stopped before surgery.

Not sure if this is normal? Chat with one of our pharmacists →

Evening primrose oil is generally considered well tolerated when taken at recommended doses, but it is not without potential risks. Commonly reported side effects include:

• Gastrointestinal symptoms such as nausea, loose stools, and abdominal discomfort

• Headache in some individuals

• Skin reactions, though these are uncommon

A historically reported concern is the potential for EPO to lower the seizure threshold, particularly when used alongside phenothiazines. This is based on older case reports and limited data rather than robust clinical evidence. As a precaution, EPO should be avoided in individuals with epilepsy or those taking medications that may affect seizure threshold, unless specifically advised otherwise by a clinician.

From a drug interaction perspective, the following precautionary considerations apply, though it should be noted that the evidence for most of these interactions is theoretical or of low certainty:

• Anticoagulants and antiplatelet agents (e.g., warfarin, aspirin, clopidogrel) — GLA may have mild antiplatelet effects, which could theoretically increase bleeding risk; patients on these medicines should consult their GP or pharmacist before taking EPO

• Perioperative use — in line with general UK guidance on herbal supplements before surgery (UK Specialist Pharmacy Service), patients are advised to stop EPO at least one to two weeks before any planned surgical procedure and to inform their surgical and anaesthetic teams

• Hormonal medications — any interaction via prostaglandin pathways is speculative; no clear clinical interaction data exist, but patients on hormone-modulating therapies should seek advice before starting EPO

Patients taking prescription medications should always inform their GP or pharmacist before starting any new supplement, including EPO.

Reporting side effects: If you experience a suspected adverse reaction to EPO or any other supplement, you can report it to the MHRA via the Yellow Card scheme at www.mhra.gov.uk/yellowcard. This scheme is open to both patients and healthcare professionals and is an important resource for UK medicine safety.

Experiencing these side effects? Our pharmacists can help you navigate them →

It is also worth noting that supplement quality and dosage can vary considerably between brands, as herbal products are not subject to the same regulatory standards as licensed medicines.

When to Seek Medical Advice for Gynaecomastia in the UK

Men with a new breast lump, nipple discharge, skin changes, or a hard irregular mass should see their GP promptly; NICE NG12 recommends urgent two-week-wait referral for suspicious male breast symptoms.

Whilst mild or transient gynaecomastia — particularly in adolescents — may resolve without intervention, there are several circumstances in which prompt medical assessment is strongly advised. Patients should contact their GP if they notice:

• A new or enlarging lump in one or both breasts

• Breast pain or tenderness that is persistent or worsening

• Nipple discharge, particularly if bloodstained

• Skin changes over the breast, such as dimpling, puckering, or redness

• Asymmetrical swelling or a hard, irregular mass

• Associated symptoms such as unexplained weight loss, fatigue, or testicular changes

In line with NICE NG12 (Suspected cancer: recognition and referral), GPs should consider an urgent two-week-wait referral to a breast clinic for males with suspicious breast symptoms, including a hard or irregular unilateral lump, skin changes suggestive of malignancy, or unilateral nipple retraction or discharge — particularly in those aged 50 and over. Referral to a breast clinic allows triple assessment (clinical examination, imaging, and biopsy where indicated), which is the appropriate pathway for investigating suspicious male breast findings.

For gynaecomastia without features of malignancy, GPs may refer to an endocrinologist, breast surgeon, or urologist depending on the suspected underlying cause. Initial investigations typically include blood tests to assess hormone levels (testosterone, oestradiol, LH, FSH, prolactin, and thyroid function), as well as liver and renal function. Where a testicular tumour or germ cell tumour is suspected, β-hCG (and in some cases AFP) should also be measured, alongside testicular examination; urgent testicular ultrasound should be arranged if a testicular mass is identified (NICE CKS: Breast symptoms – male).

Regarding the use of evening primrose oil or other herbal supplements for gynaecomastia: there is no official guidance from NICE, the NHS, or the MHRA supporting their use for this condition, and the available evidence is insufficient to recommend EPO as a treatment. Patients are encouraged to discuss any supplement use openly with their GP before starting. Self-medicating with supplements is not a substitute for clinical evaluation, and delaying assessment could result in an underlying condition going undiagnosed.

For further information, patients can access NHS resources at nhs.uk or speak with a community pharmacist, who can provide guidance on supplement safety and appropriate referral pathways.

Frequently Asked Questions